NDAINTRAVENOUSPOWDER
Approved
Mar 2022
Lifecycle
Peak
Competitive Pressure
0/100
Data completeness
3/8 — Basic
LOCAMETZ (kit for the preparation of gallium ga 68 gozetotide) by Novartis is 68 gozetotide binds to psma. First approved in 2022.
Drug data last refreshed 9h ago · AI intelligence enriched 1mo ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
LOCAMETZ is a gallium-68 labeled radiopharmaceutical kit for PET imaging that binds to PSMA (prostate-specific membrane antigen) expressed on prostate cancer cells. The gozetotide ligand targets PSMA-positive malignancies, primarily prostate cancer, enabling visualization via positron emission tomography. Gallium-68 provides the radioactive label needed for PET detection of disease.
Peak9.3 years to LOE
Early-stage specialty radiopharmaceutical in peak commercial phase with limited direct competitive pressure, supporting focused team growth in nuclear medicine channels.
Mechanism of Action
68 gozetotide binds to PSMA. It binds to cells that express PSMA, including malignant prostate cancer cells, which usually overexpress PSMA. Gallium-68 is a β+ emitting radionuclide that allows PET.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Professionals joining LOCAMETZ enter a specialized radiopharmaceutical platform at peak commercial growth with a differentiated mechanism and limited competition. This represents a niche career opportunity in an emerging modality with long patent protection and strategic importance to Novartis' oncology portfolio.
Brand ManagerMedical Science Liaison
Worked on LOCAMETZ at Novartis? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.